a proper update , page-45

Some good posts greenisgood, I agree with the vast majority of your analysis. I've been saying all along that Vitrogro will initially only be targeted at the chronic ulcer market, this is certainly where all the trials have been targeted.

@ TDA

I think you misunderstood my post mate. I'm completely aware that the current peer reviews and trial results suggests that Vitrogro is clearly superior to the current best practices in its targeted medical market (i.e. chronic non-responsive ulcers) however I'm suggesting that when you consider the sheer number of other medical markets out there (thousands literally - bacteria, viruses, diseases, cancers, mental health issues etc.) and the number of new breakthroughs coming out each day, it's not unreasonable to expect that a big pharma wouldn't be jumping out of their skin when TIS comes knocking.

They have limited monetary and human capital each year to spend on pushing new products out to market so they'll take their time to evaluate and compare the earnings potential of Vitrogro against their other investment options that they currently have on the table from other companies. Yes even those that don't fall within the chronic ulcer market, because to them its all about bang for your buck on dollars invested.

Feel free to agree/disagree with my views because this isn't a topic you can debate with one clear winner.

Personally, I think greenisgood nailed it when he said that a big pharma isn't likely to even sign a new partner unless they've completed the trials and approvals already (unless they have a cure for ageing lol) and judging by the outcome of the negotiations I think it's fair to say that Dr Mercer's expectations of what was achievable for TIS shareholders in a commercial negotiation was premature at this stage of the products life-cycle.

@ 123enen

I can certainly see what you're getting at mate from a commercial point of view and I think some of the attacks on here have been very personal and uncalled for, I would point out though that even though Vitrogro only posted an improvement of 16% above and beyond the current best practices in the market for the treatment of chronic unresponsive ulcers (a number I would personally call statistically significant but would caution that isn't necessarily likely to get any better with longer treatment times for Vitrogro) that doesn't mean that every patient currently suffering a chronic ulcer isn't going to ask their doctor to give it a go!

That's the benefit of marketing, even if the product only achieves a 16% chance of an upside for someone suffering a chronic ulcer, once the possibility of a cure is placed in the each patients mind then most of the patients in that market are now going to try it just to see how it works for them!